Mendus
5.07 SEK
-0.59 %
Less than 1K followers
IMMU
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-0.59 %
-31.39 %
-27.36 %
-7.82 %
-35.01 %
-42.06 %
-87.93 %
-96.35 %
-96.17 %
Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.
Read moreMarket cap
308.98M SEK
Turnover
257.69K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
16/12
2025
Extraordinary general meeting '25
11/2
2026
Annual report '25
8/5
2026
General meeting '26
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Mendus tillkännager milstolpe för storskalig GMP-produktion av vididencel i tillverkningsallians med NorthX Biologics
Change in number of shares and votes in Mendus AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
